on THERAVET (EPA:ALVET)
TheraVet Announces Strategic Shift to Idiopathic Pulmonary Fibrosis
TheraVet, a Belgian biotechnology company, has unveiled a major transformation project in partnership with H4Orphan to create a leader in the treatment of human idiopathic pulmonary fibrosis. This strategic repositioning includes the replacement of veterinary activities with an innovative biotech program focused on pulmonary fibrosis.
The strategic agreement will allow TheraVet to benefit from H4Orphan's flagship clinical program, which will be integrated in exchange for new shares. A phase II study will be launched within twelve months, mainly in Belgium. To finance this project, an initial refinancing of EUR 300,000 has been put in place, providing TheraVet with financial visibility until the end of March 2025.
The Extraordinary General Meeting of October 17, 2024 will determine the final validation of this operation. Ultimately, veterinary activities will be abandoned and the company name will be changed to EGEIRO Pharma to signify this new chapter.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all THERAVET news